Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach

Chagaleti, Bharath Kumar; Saravanan, Venkatesan; Vellapandian, Chitra; Kathiravan, Muthu K.

doi:10.1039/d3ra05672d

Cited by 9 publications

(3 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The compounds that ranked excellent were subjected to various in silico analysis viz., drug-likeness by Molsoft, bioactivity by Molinspiration, 20,21 ADME parameters by SWISS ADME 22 and toxicity analysis by VNN-ADMET software. 23,24…”

Section: Methodsmentioning

confidence: 99%

2,4-Substituted Oxazolones: Antioxidant Potential Exploration

Thanvi,

Chagaleti,

Srimathi R

et al. 2024

J. Young Pharm.

View full text Add to dashboard Cite

Background: This study focuses on the development of a novel and environmentally friendly synthetic methodology for the production of a series of six 4-benzylidene-2-phenyloxazol-5(4H)-one derivative (M1-M6). The approach involves a one-pot procedure utilizing hippuric acid, fused sodium acetate and various substituted aromatic aldehydes in the presence of acetic anhydride. Purpose: The primary objective is to explore the potential antioxidant properties of the synthesized compounds and contribute to the understanding of azlactones as promising antioxidants. The study integrates experimental synthesis with in silico methodologies to comprehensively characterize the chemical and biological properties of the derivatives. Materials and Methods:The synthesis process employed a combination of hippuric acid, fused sodium acetate and substituted aromatic aldehydes in a one-pot procedure. The chemical structures of the derivatives were characterized and validated through in silico techniques, including docking studies, drug-likeness assessments, bioactivity predictions, ADME profiling and toxicity evaluations. Results: The in silico analyses provided insights into the molecular interactions, pharmacokinetic properties and safety profiles of the synthesized compounds. In vitro antioxidant potential was systematically investigated using the DPPH method, with compounds M 3 and M 5 demonstrating significant antioxidant activity at a concentration 40 µg/ mL showing (88% inhibition) and (85.7% inhibition) respectively, surpassing ascorbic acid as the reference standard. Conclusion: This study successfully explores azlactones as potential antioxidants, combining experimental synthesis and in silico methodologies to characterize the chemical and biological properties of the synthesized derivatives. The notable antioxidant activity of compounds M 3 and M 5 positions them as promising candidates for further investigation. The findings establish a foundation for future research and development of these compounds in potential antioxidant-related therapeutic interventions.

show abstract

Section: Methodsmentioning

confidence: 99%

2,4-Substituted Oxazolones: Antioxidant Potential Exploration

Thanvi,

Chagaleti,

Srimathi R

et al. 2024

J. Young Pharm.

View full text Add to dashboard Cite

show abstract

“…A higher score is indicative of stronger activity, re ecting the e cacy of the compound in biological interactions. Accordingly, a bioactivity score above 0.00 is indicative of a compound with substantial bioactivity, while scores ranging from − 0.50 to 0.00 suggest moderate activity [59]. [59]Conversely, compounds are classi ed as inactive if their scores fall below or equal to -0.50.…”

Section: Bioactivitymentioning

confidence: 99%

Molecular modeling studies of Pyrazolopyrimidine Derivatives as potent Cyclin Dependent Kinase-2 inhibitors

Chagaleti,

2024

Preprint

Self Cite

View full text Add to dashboard Cite

This study addresses the pressing need for innovative cancer treatments in the face of global challenges posed by the widespread occurrence of cancer and increasing treatment resistance. The study looks at cyclin-dependent kinase-2 (CDK2) and uses a methodical computer approach to find possible anticancer compounds with pyrazole and pyrimidine structures. (QSAR) quantitative structure-activity relationship has become crucial in lead optimization over the last three decades. A set of 45 pyrazolopyrimidine derivatives with known IC50 values were used to create and test models using QSARINS software. Model 4, with its high predictive performance (R2 = 0.9100, R2adj = 0.8900, LOF = 0.0394), emerges as the most reliable. The resulting QSAR model proves stable, predictive, and robust, effectively representing the original dataset. Active molecular descriptors are identified for predicting the structure-activity relationship. We used SAR analysis and model equation parameters to create sixty compounds and tested them for their predicted bioactivity using Model 4. These compounds are a series with pyrazolopyrimidine-fused piperidine and hybrid moieties, such as methanethione (20), ethenone (20), and benzamide (20). Among the designed series, 16 compounds exhibited pIC50 values exceeding 7, indicating that they were hit molecules represented as C1-C16. These obtained hit molecules undergo further screening with ADMET, molecular docking, and molecular dynamics simulations. C3 and C7, revealed in docking studies with low-energy conformations and sustained binding during simulations, consistently align their binding modes with the standard drug roscovitine. These compounds emerge as promising leads for targeting CDK2 in the development of groundbreaking cancer therapies.

show abstract

“…Cyclin-Dependent Kinase (CDK) 4/6 inhibitors, including abemaciclib, palbociclib and ribociclib constitute important components of the current standard first-line treatment for patients with HR+/HER2-metastatic breast cancer (mBC) ( Chagaleti et al, 2023 ; Chang and Lam, 2023 ; Geisler et al, 2023 ). The combination of Palbociclib with aromatase inhibitors or fulvestrant has emerged as a pivotal advancement, reshaping the treatment paradigms for HR+/HER2-mBC ( Bilgin et al, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis

Moraes,

Pereira,

Sano

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Exploring cyclin-dependent kinase inhibitors: a comprehensive study in search of CDK-6 inhibitors using a pharmacophore modelling and dynamics approach

Abstract: Design and development of novel CDK-6 inhibitors by computational investigation using a ligand based pharmacophore model, ADMET studies, molecular docking and dynamics.

Cited by 9 publications

References 70 publications

2,4-Substituted Oxazolones: Antioxidant Potential Exploration

2,4-Substituted Oxazolones: Antioxidant Potential Exploration

Molecular modeling studies of Pyrazolopyrimidine Derivatives as potent Cyclin Dependent Kinase-2 inhibitors

Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis

Contact Info

Product

Resources

About